Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multilineage glycoprotein cytokine which is synthesised by a variety of cell types, such as T and B lymphocytes (Chan et al., 1986; Herrmann et al., 1988; Pluznik et al., 1989) , macrophages (Thorens et al., 1987; Fibbe et al., 1988) , fibroblasts (Kaushansky et al., 1988) and endothelial cells (Sieff et al., 1987) . Expression of GM-CSF has also been documented in certain solid tumours (Zinzar et al., 1985) , and myeloid leukaemia cells are also believed to be a potential pathophysiological source of this cytokine (Oklamura et al., 1988; Fiedler et al., 1990) . We have recently shown that tumour-infiltrating lymphocytes (TILs) from renal cell cancer (RCC) are able to release a wide array of various cytokines, including GM-CSF (Steger et al., 1994) . GM-CSF acts as a potent growth factor both in vitro and in vivo, stimulating proliferation and maturation of myeloid progenitor cells, giving rise to neutrophilic and eosinophilic granulocytes and monocytes (Begley et al., 1988; Lopez et al., 1986; Metcalf et al., 1986; Silberstein et al., 1986; Kaufman et al., 1989) .
GM-CSF is involved in the host defence mechanisms and is a potent factor in activating macrophages for tumour cell killing. Activated macrophages can be non-specifically cytotoxic for tumour cells in an MHC-independent fashion (Fidler and Schroit, 1988) . They also can specifically recognise tumour cells in vivo, thus playing an important role in host surveillance against autochthonous transformed neoplastic cells (Fidler, 1985) . Vaccination with irradiated tumour cells engineered to secrete murine GM-CSF has been shown to induce specific anti-tumour immunity (Dranoff et al., 1993) . TILs from RCC are able to secrete GM-CSF upon stimulation (Steger et al., 1994) , and this ability to secrete GM-CSF upon autologous tumour stimulation was recently shown to correlate positively with the clinical response after TIL immunotherapy in melanoma patients (Schwartzentruber et al., 1994) . In addition, there are reports that GM-CSF can stimulate proliferation or function of T-cell lines. It has been demonstrated that GM-CSF can serve as a growth factor for the IL-2/IL4 dependent T-cell line HT-2, acting through a pathway which is distinct from that of IL-2 or IL4 (Kupper et al., 1987; Woods et al., 1987 ). Herbelin et al. (1989 reported that GM-CSF and IL-1 act synergistically to stimulate thymocyte proliferation via an IL-2-independent pathway. Santoli et al. (1988) demonstrated that GM-CSF can support the growth of cells within the lymphoid lineage and exert potent amplifying effects on IL-2-induced T-cell growth in vitro. Moreover, in a recent evaluation of GM-CSF by Masucci et al. (1990) , it was demonstrated that GM-CSF and IL-2 act synergistically on peripheral lymphocytes with the induction of a highly effective cytotoxic cell population.
IL-2-based immunotherapy and adoptive immunotherapy with in vitro-activated lymphocyte-activated killer (LAK) cells and TILs are increasingly applied in the therapy of human solid tumours Topalian et al., 1988 Table I . GM-CSF alone and when added to (Table IV) supplemented with IL-2 or GM-CSF and IL-2 revealed similar percentages of cells positive for CD3 and CD3/CD56 respectively. TILs grown with 1000 nmol ml-' GM-CSF and IL-2 showed a significantly higher percentage of CD56+ cells, while expression of CD56 was unchanged in TILs activated with 500 nmol ml-' GM-CSF + IL-2 when compared with TILs activated with IL-2 alone. The percentages of CD8+ and CD4+ cells were similar independent of the culture conditions. Expression of the IL-2 receptor (CD25) was unaffected by GM-CSF.
GM-CSF receptor analysis
Two TIL populations were analysed for their ability to express the GM-CSF receptor. One population was activated with IL-2 400 U ml-' alone and the other with IL-2 400Uml' +GM-CSF 100OnmolmlV'. In neither of the (Lopez et al., 1983; Vadas et al., 1983; Weisbart et al., 1985 Weisbart et al., , 1986 . Although still somewhat controversial, some wel-designed in vitro studies have ckarly demonstrated that the activity of GM-CSF is not resticted to monocytes/macrophage and granulocytes. Also, the proliferation and growth of T cells (Kupper et al., 1987; Woods et al., 1987; Santoli et al., 1988; Herbelin et al., 1989 Herbelin et al., , 1990 as well as their in vitro killing behaviour (Masucci et al., 1990) can be modulated by GM-CSF.
The first goal of our study was to investigate the ability of GM-CSF to induce TIL development from single-:ell suspensions derived from RCC. GM-CSF at both concentrations (500 nmol ml-', 1000 nmol ml-') investigated failed to induce TIL development from RCC specimens when used as single activator. Also, when GM-CSF was added to tumour/ lymphocyte suspensions together with suboptimal concentrations of IL-2 (8, 40 U ml-'), no TIL development was observed. Only when the primary cell cultures were supplmented with GM-CSF and concentrations of IL-2 (400 U ml-') which sufficed alone for the activation and expansion of TILs was TIL development observed. Thus, GM-CSF cannot be asumed to be an independent growth factor for TILs derived from RCC, nor does GM-CSF facilitate the development of TILs when suboptimal doses of IL-2 are used.
However, TILs activated with GM-CSF and IL-2 differ signifiantly, in terms of proliferation, expansion and in vitro kilng behaviour, from TILs activated with EL-2 alone. TILs grown with GM-CSF + IL-2 proliferated better than TILs activated with IL-2 alone, but the possible culture period was not affected. This enhancement of proliferation, coupled with similar time periods for which TILs could be maintained in culture, resulted in a snificantly higher and more rapid expansion for TILs grown with either 500 umol ml-' or 1000 umol ml-' GM-CSF and IL-2. These results are in good agreement with the limited data available for peripheral T cells. Santoli et al. (1988) have demonstrated that GM-CSF enhances the short-term responsiveness of peripheral T cells to IL-2, and GM-CSF also potentiates the long-term growth of non-activated human lymphocytes and of lectin-and Agactivated T cells in the presence of IL-2. Although in clnical investigations the number of activated cells reinfused to the patients and the effectiveness of treatment demonstrates no correlation thus far, most dinical protocols require the expansion of TIL cultures to at kast 1 x 109 to 1 x 101" cls.
Such cell counts are usually reached within 4-6 weeks of culture . Thus, this higher proliferation rate of TILs resulting in high cell counts when GM-CSF + IL-2 are used for activation would shorten the culture period, allowing an earlier onset of adoptive immunotherapy after surgical removal of the primary tumour.
Unlike TILs derived from melanoma (Itoh et al., 1986; Muul et al., 1987) TILs activated with GM-CSF and IL-2 showed a different killing behaviour in vitro when compared with the corresponding TIL cultures activated with IL-2 alone. The addition of GM-CSF to the culture medium resulted in enhanced killng of the autologous tumour target and the allogeneic renal tumour target. In contrast, lysis of the NK-sensitive K562 erythroleukaemia cell line and the NK-reistant Daudi lymphoma cell line ained unaffected. The percentag of CD3+, CD3+/CD56+, CD4+ and CD8+ cells were similar in all TIL populations independent of the culture condition.
The higher percentage of cells positive for the NK marker CD56 in TIL populations cultured with high concentrations of GM-CSF and IL-2 appears not to be responsible for the demonstrated enhanced kIilling, since TIL cultures supplmented with the lower concentration of GM-CSF also showed enhanced klling and a similar percentage of these cells were CD56+ when compared with TILs activated with IL-2. Furthrmore, the killing activity against the NKsenstive K562 cell hne rained uaffected independent of the concentration of GM-CSF used. The differences in the pattern of target lysis between TEL populations activated with IL-2 or GM-CSF + IL-2 were maintained over time in our experiments. Despite this of lytic activity of the autolgous tumour target the killing behaviour of the tested TIL populations was always non-specific as the allogeneic targets were always lysed equally well or better.
However, the fact remains that GM-CSF is able to enhance the lytic activity of RCC TILs against renal targets only.
These data are in part imilar to findin rding the ability of GM-CSF to induce LAK-cell activity in peripheral Iymphocytes. Masucci et al. (1990) Although the presence of a specific receptor might be assumed and the murine receptor specific for GM-CSF has been demonsta in two cell ines of T-lymphoyte origin (Park et al., 1986) , the presence of the GM-CSF receptor on human lymphocytes has not been thoroughly investigated and has not as yet been demonsta (Gasson, 1991) . We
were not able to demonstrate the presei c of receptors secific for GM-CSF on the surface of mature RCC TILs. Although the expression of low nmmbers of the GM-CSF receptor on a minor subfraction of the TIL populations invesited might have been undetectable with the ligandbindng assay used, the pathway through which GM-CSF modulates T-cell actions, or at least TIL actions, appears to be an indiret rather than a direct one. After tumour processing the singkl l suspensions also contain macrphages and other mononuclear cells. Since GM-CSF has been shown to activate M opges to enhance non-specific and specific immune reonses tgainst tumour cells, it might be speculated that one of these indirect effects could be the activation and stimulaton of cells other than lymphocytes to reles cytokines with T-cell-activating propertes In summary, GM-CSF is not able to induce TIL development from RCC or to facitate TIL activation induced by IL-2. However, TILs from RCC cultured with IL-2 and GM-CSF demonstrate snificantly higher proliferation, resulting in a higher expansion of TIL cultures, and exert a higher killing activity against renal tumour targets in vitro.
These findings provide a rational basis for the use of GM-CSF in the expansion of TILs, and further investigations are warranted. Clinical experience with systemic GM-CSF is more or less lhimted to the us of this cytokie to shorten chemotherapy-induced leucpenia. Unlike sysemic IL-2 administration, GM-CSF application is rarely associated with serious sideeffcts (Morstyn et al., 1988; Horn et al., 1991; Steger et al., 1992) . Based on our results and the known properts of GM-CSF in improving host defence in immunooompromised patients by means of enhancd cytokine release and enhancement of cytolytic activity of neutrophils, eonnophils and macrophages (Weisbart, 1989) , one might also speculate that GM-CSF could be of therapeutic value when admin lly to patints reciving IL-2-based adoptive immunotherapy with TLs. The mode of action of GM-CSF in enhancing T-cell-mediated cytotoxic effects is not completely understood. Further in vitro and in vivo investigations with TILs and GM-CSF are needed to elucidate these issues.
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